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Abstract
 Irritable bowel syndrome & depression are common comorbidities, however there is
a wide variability regarding the appropriate treatment regimens for these patients.
 IBS is classified as a functional bowel disease in which patients suffer from
recurrent abdominal pain or discomfort associated with alterations in bowel habits.
 While the cause of IBS is multifactorial, studies have revealed that the dysfunction
of the brain-gut pathways are a culprit to disease appearance and progression, as
seen in the biopsychosocial model of IBS. This model proposes that abdominal
symptoms secondarily impact anxiety & depression symptoms and that
psychological factors influence physiologic aspects such as motor functions, sensory
threshold & stress reactivity of the gut through the vagal & sympathetic afferents.
 Due to the complexity of the causal mechanisms that produce symptoms of IBS with
depression, there is some uncertainty regarding the best treatment regimen for these
patients.
 Commonly, patients are advised to increase physical activity, reduce stress &
implement dietary modifications. Pharmacotherapy may be advised for some,
depending on their symptoms, & may include antidepressants, antispasmodics or
laxatives.
 There is not a standardized method of treating IBS with comorbid depression,
therefore symptom management must be performed on a patient-by-patient basis.

http://www.nutritionist-resource.org.uk/press/ibs-awareness-infographic/

Introduction
 Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder (FGID) that
is classically characterized by recurrent abdominal pain or discomfort associated
with alterations in bowel habits.
 3 subtypes of IBS: IBS-D (diarrhea predominant), IBS-C (predominant constipation)
and IBS-M (mix of diarrhea & constipation). Pathophysiology is multifactorial, but
common triggers include an acute GI infection & food.
 Those with IBS & comorbid depression often experience decreased quality of life
(QOL) due to chronic abdominal pain & an increase in healthcare costs (Sibelli et al,
2016).
 There is a two-way communication that takes place between the intestinal wall &
the CNS via the vagus nerve, which runs from the brainstem to the gut, and is
responsible for relaying essential stress-response signals. This explains why CNS
disorders are so often accompanied by digestive issues, & irregularities in the
digestive system directly shape both cognitive & emotional states.
 Depression-induced slow colonic motility is likely to compound the severity of gut
dysfunction & go on to further destabilize the intestinal microbiota, which results in
patients with IBS having instability of the microbiota (Park et al, 2013). The
destabilization of the microbiota may then contribute to gut dysfunction as well as
behavioral changes, as seen with the psychiatric comorbidity commonly found in
IBS patients.

Statement of the Problem
 Although IBS & depression are common comorbidities of one another, there is still
uncertainty on how to best treat these patients.
 There is also uncertainty in regards to whether IBS symptoms aggravate a patient's
depression versus depression exacerbating the IBS symptoms.

Discussion

Research Questions
 What is the link between IBS & depression?
 What are the causal mechanisms for triggers of IBS symptoms?
 What are the best treatment options for patients with IBS & comorbid depression?




Literature Review
PATHOPHYSIOLOGY OF IBS AND DEPRESSION
 The biopsychosocial model describes how IBS pathophysiology may be due to various
interactions between biological & psychosocial factors. External stressors & major life
events may interrupt the regulation of the brain-gut axis & ultimately influence IBS onset,
symptom severity and treatment response. The abdominal symptoms may also
secondarily impact anxiety/depression symptoms (Sibelli et al., 2016).
 Up to 60% of those with FGIDs suffer from psychiatric comorbidities (Park et al.,
2013).
 Stress can lead to abnormal GI motility and visceral hypersensitivity through modulation
of the HPA axis. With this, there is an abnormal expression of corticotropin releasing
factor (CRF), & an increase in CRF expression can lead to anxiety &/or depression.
Those with IBS & depression exhibit an imbalance of the inflammatory response, which
in turn, leads to the induction of the corresponding digestive & psychiatric symptoms.
Therefore, the increased CRF expression that leads to anxiety &/or depression also
contributes to IBS symptoms (Jizhong, Qiaomin, Chao & Yanqing, 2016).
 Gut microbiota is altered in IBS patients, & it is still uncertain whether this dysbiosis
initiates anxiety & depressive symptoms (by increased gut permeability, secretion of
endotoxin and/or neuropeptides, inflammation, altered nutrient absorption, & autonomic
nervous system modulation) or if anxiety & depression prompt gastrointestinal disorders
(Muscatello, Bruno, Mento, Pandolfo & Zoccali, 2016).
CAUSAL MECHANISMS FOR TRIGGERS OF IBS SYMPTOMS
 Genetic predispositions & early-life stressors (physical/sexual/emotional abuse, death
of a parent, parental divorce, etc.) could impact the bidirectional pathways between gut &
brain. This will, in turn, influence one’s susceptibility to develop IBS, with the
unfortunate possibility of each successive exposure to stressors exacerbating the IBS
symptoms.
 Anger, anxiety & depression have been linked to visceral & pain hypersensitivity. With
the occurrence of negative emotions, visceral sensations are often more noticeable &
considered to be painful (Muscatello et al., 2016).
 Koloski, Jones & Talley (2016) calculated that in 1/3 of people a mood disorder
precedes FGID, and in 2/3 of people a FGID precedes the mood disorder.
 Conversely, Sibelli et al (2016) concluded that the overall risk of developing IBS was
double for subjects that had anxiety &/or depression at baseline compared to those who
did not. This study also goes on to explain that even though anxiety & depression may
increase a person’s risk of developing IBS in the future, findings suggest that these are
not the singular cause of IBS.
 A common trigger for disease onset is an acute GI infections, with studies estimating
around 5-32% of patients developing their IBS after suffering from a GI infection (Sibelli
et al., 2016). This is often termed as post infectious IBS, or PI-IBS.
 Anxiety in IBS patients was more pronounced for those with several comorbidities,
especially in younger adults. Depression displayed the same pattern as anxiety, & there
was no significant relation between age & medical comorbidities in predicting IBS
symptom severity or QOL (Thakur, Quigley, El-Serag, Gudleski & Lackner, 2016).
CURRENT TREATMENT OPTIONS FOR IBS PATIENTS WITH COMORBID DEPRESSION
 There is no universally accepted method to cure IBS, & the subcategories of this
disease complicate blanket treatment options.
 Treatment is individualized to the patient’s most bothersome symptoms.
 IBS symptoms, disease specific QOL, fatigue, depression/anxiety were all improved with
physical activity when compared to baseline (Johannesson, Ringstrӧm, Abrahamsson &
Sadik, 2015).
 It is recommended that patients follow the low fermentable oligosaccharides,
disaccharides, monosaccharides and polyols (FODMAP) diet.
 Antidepressants are often recommended as a form of treatment, & it was discovered that
tricyclic antidepressants can improve global symptoms of IBS & that there was
insufficient evidence to confirm the effectiveness of selective serotonin reuptake
inhibitors (Xie et al, 2015).
 There may be some improvement in the global symptoms of IBS with the use of
probiotics, specifically the use of the Bifidobacterium infantis strand, which was found
to be more effective in decreasing abdominal pain when compared to Lactobacillus
salivarius (Vanuytsel, Tack & Boeckxstaens, 2014).
 Other options include antispasmodics for IBS-D & laxatives for IBS-C.
 Berberine hydrochloride, a traditional Chinese herb, reduces anxiety & depression scores
as well as IBS-D symptoms and overall QOL (Chen et al., 2015).
 Gut-directed hypnotherapy displayed superior efficacy to the FODMAP diet on
psychological indices & GI symptoms (Peters, Yao, Philpott, Yelland, Muir & Gibson,
2016).
 Moxibustion can significantly improve the symptoms of D-IBS, & may be more effective
than EA in these patients (Zhao et al., 2015).











Applicability to Clinical Practice

WHAT IS THE LINK BETWEEN IBS AND DEPRESSION?
The pathophysiology of IBS is complex, however it is probable that dysfunction
of the brain-gut pathways contributes to the appearance of the disease.
Those with IBS & depression display an imbalance of the inflammatory response,
which then leads to the induction of the corresponding digestive and psychiatric
symptoms. (Jizhong, Qiaomin, Chao & Yanqing, 2016).
Patients with IBS have been discovered to have altered gut microbiota
(Muscatello, Bruno, Mento, Pandolfo & Zoccali, 2016).
Other studies have eluded to the concept that psychiatric symptoms occur before
IBS symptoms present (Sibelli et al, 2016).
WHAT ARE THE CAUSAL MECHANISMS FOR TRIGGERS OF IBS SYMPTOMS?
External stressors or early life stressors (Sibelli et al, 2016).
Feelings of anger, anxiety & depression have been linked to visceral and pain
hypersensitivity (Muscatello et al., 2016).
The mood disorder may precedes the FGID symptoms, or vice versa (Koloski et
al., 2016).
Anxiety & depression may increase a person’s risk of developing IBS in the
future, however findings suggest that these are not the singular cause of IBS
(Sibelli et al, 2016).
Acute GI infections are another common trigger for IBS (Sibelli et al., 2016).

 Importance of screening & treating anxiety/depression in patients with IBS, as psychological factors
play an important role in symptom severity & persistence, as well as motivation to seek treatment
and one’s response to treatment.
 Educating patients on disease process & how to better manage their symptoms would ideally be the
first step in creating their personalized treatment regimen.
 The symptoms of IBS can be overwhelming for patients, so it is important to reiterate that even
though their IBS is causing them a great deal of pain & discomfort, it does not cause permanent
harm to their bowels or lead to cancer.
 Be aware of potential predisposing factors of IBS.
 Some options for treatment include lifestyle modifications such as increasing physical activity,
decreasing stress & dietary modifications. Patients may also benefit from probiotics or alternative
medicine such as hypnotherapy or acupuncture.
 There may be a need for antidepressants, antispasmodics or laxatives.
 There is not a one size fits all approach to treatment of these patients, so often it is a process of
trial and error. It is important that the primary provider is aware of the communities
resources, as well as when and where to refer patients if needed.
 These patients often suffer from a decreased QOL & may be frustrated through the trials of finding
an ideal treatment regimen. It is therefore imperative for a provider to be patient, supportive &
evoke hope that an improved QOL through symptom management is obtainable.

WHAT ARE THE BEST TREATMENT OPTIONS FOR PATIENTS WITH IBS &
COMORBID DEPRESSION?
 There is no standardized method to cure IBS.
 For some, decreasing the burden of symptoms from IBS may be as simple as
increasing physical activity & dietary modifications. Patients are usually advised
to follow the low FODMAP diet, as it is a beneficial treatment of IBS.
 TCAs can improve global symptoms of IBS and there is insufficient evidence to
confirm the effectiveness of SSRIs. Some patients may still prefer SSRIs solely
for their depression symptoms (Xie et al, 2015).
 Probiotics have been speculated to improve IBS symptoms via their effects
intestinal immune function, visceral hypersensitivity, gastrointestinal motility,
intestinal permeability & microbiota (Vanuytsel et al., 2014). This is especially
with the Bifidobacterium infantis strand, which was found to be more effective in
decreasing abdominal pain when compared to Lactobacillus salivarius (Vanuytsel
et al., 2014).
 Other pharmacologic options for symptom relief include antispasmodics for the
IBS-D subclass, & laxatives for the IBS-C subclass.
 Some alternative medicine options that have been studied and appear promising
for IBS symptom relief, including herbs, hypnotherapy & acupuncture.

http://perspectivesclinic.com/health-psychology/

http://www.suppleceutical.com/

http://www.bestherbalhealth.com/irritable-bowel-syndrome-ibs-5-causes-5-easy-treatments/
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